EnBiotix, Inc. is a bioengineering company that specializes in developing therapies for chronic and recurrent pulmonary infections, particularly those caused by drug-resistant bacteria. Founded in 2010 and headquartered in Boston, Massachusetts, the company employs innovative platforms, including an anti-persisters platform that enhances antibiotic effectiveness, an engineered bacteriophage platform that targets infections, and a tunable target degradation platform that modifies protein functions. EnBiotix has a diverse clinical pipeline, with notable products such as EBX-001 for P. aeruginosa infections in cystic fibrosis patients, EBX-002 for catheter-associated urinary tract infections, and EPP-001 for prosthetic joint infections. The company's mission is to combat the global rise of antibiotic resistance by revitalizing existing antibiotic classes and addressing a significant market need for effective treatments in the healthcare landscape.
Antimicrobial peptides (AMPs) are found in virtually every species, from microbes to humans. They comprise the first line of defense against infection through the innate immune system. The AMPT portfolio of unique antimicrobial peptides overcomes many of the issues associated with AMPs as anti-bacterial therapeutics, most notably potency, spectrum, stability and toxicity. The unique mechanism of action of these compounds and the low rate of resistance development positions these molecules as the next generation of novel anti-bacterials. In addition to their potential as stand-alone therapeutics, the AMPT portfolio, in combination with EnBiotix’s engineered bacteriophage platform, further enhances the scope and capabilities of both platforms.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.